Advertisement

---

ACTAVIS, INC.

Actavis Receives Canadian Approval to Market FIBRISTAL™ - A Treatment for Symptoms of Uterine Fibroids

[2013-06-25] -


Actavis And Kissei File Lawsuits Against Sandoz And Hetero For Infringement Of Rapaflo® Patent

[2013-06-19] -


Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition

[2013-06-18] -


U.S. Supreme Court Reverses U.S. Court of Appeals Decision in FTC v. Actavis

[2013-06-17] -


Actavis and Medicines360 Announce Partnership to Advance Women's Access to Affordable IUDs

[2013-06-11] - - Actavis Acquires U.S. Commercial Rights for LNG20 Intrauterine Device (IUD) -


Actavis Confirms Generic Diprivan® Patent Challenge

[2013-06-07] -


Actavis Confirms Generic Safyral® Patent Challenge

[2013-06-05] -


Actavis, Inc. to Present at the Goldman Sachs 34th Annual Global Healthcare Conference 2013

[2013-06-04] -


Actavis Confirms Appeals Court Issues Injunction Related to Generic Pulmicort RESPULES® Distribution

[2013-05-24] -


Actavis, Inc. to Present at the Sanford C. Bernstein Twenty-Ninth Annual Strategic Decisions Conference 2013

[2013-05-24] -


Actavis to Acquire Warner Chilcott to Create Premier $11 Billion Revenue Global Specialty Pharmaceutical Company

[2013-05-20] -


Actavis to Acquire Warner Chilcott to Create Premier $11 Billion Revenue Global Specialty Pharmaceutical Company

[2013-05-20] - - Top 3 U.S. ~$3.0 Billion Revenue Specialty Brand Business -
- Expands Portfolio and Pipeline in Core Areas of Women's Health and Urology -
- Adds Gastroenterology and Dermatology Franchises and Infrastructure -
- Stronger Commercial Presence to Support Expanded Brand Pipeline -
- Immediately Accretive With Opportunities for Substantial Operational Synergies and Tax Savings -
- Combination Expected to Generate Strong EBITDA and Cash from Operations -
- All Stock Transaction Further Enables Rapid Deleveraging -
- Anticipate Closing by Year End 2013, Pending Approvals -


Announcement Under Irish Takeover Rules Relevant Securities in Issue

[2013-05-14] -


Announcement Under Irish Takeover Rules Relevant Securities in Issue

[2013-05-14] -


Actavis Cancels Presentation at Bank of America Merrill Lynch Healthcare Conference

[2013-05-13] -


Actavis' NDA for Progestin-Only Patch Accepted for Filing by FDA

[2013-05-13] -


Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc

[2013-05-10] -


Actavis Confirms District Court Ruling In Generic Lialda® Patent Suit

[2013-05-09] -


1 - 2
Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers